Longeveron to Present at Emerging Growth Virtual Conference on June 12, 2024

Longeveron Inc., a biotechnology firm trading under NASDAQ: LGVN, announced its participation in the Emerging Growth Virtual Conference scheduled for June 12-13, 2024. The company's presentation is set for Wednesday, June 12, at 1:45 p.m. ET. Interested individuals can access the webcast via the “Events and Presentations” section on Longeveron's website. Following the conference, a replay of the webcast will be available online for 180 days. Attendees can submit questions ahead of time to Questions@EmergingGrowth.com or ask them during the event.

Longeveron Inc. specializes in developing regenerative medical treatments to meet unmet medical needs. Their leading investigational product, Lomecel-B™, is an allogeneic medicinal signaling cell (MSC) therapy derived from the bone marrow of young, healthy adult donors. Lomecel-B™ is believed to have several possible mechanisms of action, including promoting vascular health, regeneration, anti-inflammation, and tissue repair. These features grant it broad potential applications across various disease areas.

Currently, Longeveron is advancing research in three primary areas: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. For additional information, individuals are encouraged to visit Longeveron's website or follow their updates on LinkedIn, X, and Instagram.